{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T13:03:25Z","timestamp":1784293405243,"version":"3.55.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T00:00:00Z","timestamp":1780099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T00:00:00Z","timestamp":1780099200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100004823","name":"Nagoya University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004823","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s40272-026-00754-5","type":"journal-article","created":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T07:37:47Z","timestamp":1780126667000},"page":"417-427","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Sirolimus Therapy and Dyslipidemia in Neonates and Infants: A Retrospective Cohort and Pharmacovigilance Analysis"],"prefix":"10.1007","volume":"28","author":[{"given":"Akinobu","family":"Taniguchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basile","family":"Chr\u00e9tien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuto","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryosuke","family":"Miura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuichi","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiko","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukako","family":"Muramatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiaki","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0367-8557","authenticated-orcid":false,"given":"Kazuki","family":"Nishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,30]]},"reference":[{"key":"754_CR1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000008871","author":"I Amodeo","year":"2017","unstructured":"Amodeo I, Colnaghi M, Raffaeli G, et al. The use of sirolimus in the treatment of giant cystic lymphangioma: four case reports and update of medical therapy. Medicine. 2017. https:\/\/doi.org\/10.1097\/MD.0000000000008871.","journal-title":"Medicine"},{"key":"754_CR2","doi-asserted-by":"publisher","DOI":"10.1111\/pde.14853","author":"H Clark","year":"2021","unstructured":"Clark H, Schulte R, Haggstrom AN. Severe hypertriglyceridemia following sirolimus use in an infant. Pediatr Dermatol. 2021. https:\/\/doi.org\/10.1111\/pde.14853.","journal-title":"Pediatr Dermatol"},{"key":"754_CR3","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1310967","author":"S Senniappan","year":"2014","unstructured":"Senniappan S, Alexandrescu S, Tatevian N, et al. Sirolimus therapy in infants with severe hyperinsulinemic hypoglycemia. N Engl J Med. 2014. https:\/\/doi.org\/10.1056\/nejmoa1310967.","journal-title":"N Engl J Med"},{"key":"754_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2023.1304133","author":"M Kim","year":"2023","unstructured":"Kim M, Hong KT, Park HJ, et al. Clinical effectiveness and safety of sirolimus in pediatric patients with complex vascular anomalies: necessitating personalized and comprehensive approaches. Front Pediatr. 2023. https:\/\/doi.org\/10.3389\/fped.2023.1304133.","journal-title":"Front Pediatr"},{"key":"754_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvs.2019.06.217","author":"C Freixo","year":"2020","unstructured":"Freixo C, Ferreira V, Martins J, et al. Efficacy and safety of sirolimus in the treatment of vascular anomalies: a systematic review. J Vasc Surg. 2020. https:\/\/doi.org\/10.1016\/j.jvs.2019.06.217.","journal-title":"J Vasc Surg"},{"key":"754_CR6","doi-asserted-by":"publisher","DOI":"10.1053\/jlts.2001.23916","author":"JF Trotter","year":"2001","unstructured":"Trotter JF, Wachs ME, Trouillot TE, et al. Dyslipidemia during sirolimus therapy in liver transplant recipients occurs with concomitant cyclosporine but not tacrolimus. Liver Transpl. 2001. https:\/\/doi.org\/10.1053\/jlts.2001.23916.","journal-title":"Liver Transpl"},{"key":"754_CR7","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.m100392-jlr200","author":"JD Morrisett","year":"2002","unstructured":"Morrisett JD, Abdel-Fattah G, Hoogeveen R, et al. Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients. J Lipid Res. 2002. https:\/\/doi.org\/10.1194\/jlr.m100392-jlr200.","journal-title":"J Lipid Res"},{"key":"754_CR8","doi-asserted-by":"publisher","DOI":"10.1097\/jova.0000000000000065","author":"P Triana","year":"2023","unstructured":"Triana P, D\u00edez-Sebasti\u00e1n J, Rodriguez-Laguna L, et al. Sirolimus early treatment in vascular anomalies leads to a better response. J Vasc Anomalies. 2023. https:\/\/doi.org\/10.1097\/jova.0000000000000065.","journal-title":"J Vasc Anomalies"},{"issue":"3","key":"754_CR9","doi-asserted-by":"publisher","DOI":"10.4174\/astr.2024.106.3.125","volume":"106","author":"YJ Cho","year":"2024","unstructured":"Cho YJ, Kwon H, Ha S, et al. Successful outcome with oral sirolimus treatment for complicated lymphatic malformations: a retrospective multicenter cohort study. Ann Surg Treat Res. 2024;106(3):125. https:\/\/doi.org\/10.4174\/astr.2024.106.3.125.","journal-title":"Ann Surg Treat Res"},{"key":"754_CR10","doi-asserted-by":"publisher","DOI":"10.1007\/s00405-023-07991-1","author":"AM Saibene","year":"2023","unstructured":"Saibene AM, Rosso C, Felisati G, et al. Sirolimus treatment for paediatric head and neck lymphatic malformations: a systematic review. Eur Arch Otorhinolaryngol. 2023. https:\/\/doi.org\/10.1007\/s00405-023-07991-1.","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"754_CR11","doi-asserted-by":"publisher","DOI":"10.1007\/s00405-022-07378-8","author":"S Wiegand","year":"2022","unstructured":"Wiegand S, Dietz A, Wichmann G. Efficacy of sirolimus in children with lymphatic malformations of the head and neck. Eur Arch Otorhinolaryngol. 2022. https:\/\/doi.org\/10.1007\/s00405-022-07378-8.","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"754_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/children9091295","author":"Z Zhang","year":"2022","unstructured":"Zhang Z, Li Y, Zhang G, et al. Safety evaluation of oral sirolimus in the treatment of childhood diseases: a systematic review. Children. 2022. https:\/\/doi.org\/10.3390\/children9091295.","journal-title":"Children"},{"key":"754_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/ph17101255","author":"YH Hu","year":"2024","unstructured":"Hu YH, Zhao YT, Guo HL, et al. Therapeutic drug monitoring for sirolimus in children with vascular anomalies: what can we learn from a retrospective study. Pharmaceuticals. 2024. https:\/\/doi.org\/10.3390\/ph17101255.","journal-title":"Pharmaceuticals"},{"key":"754_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2024.1434493","author":"A Neirotti","year":"2024","unstructured":"Neirotti A, Barat V, Coppo P, et al. Therapy with sirolimus in vascular anomalies: the experience of two Italian centers on 14 pediatric patients. Front Pediatr. 2024. https:\/\/doi.org\/10.3389\/fped.2024.1434493.","journal-title":"Front Pediatr"},{"key":"754_CR15","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-023-00476-7","author":"D \u015amia\u0142ek","year":"2023","unstructured":"\u015amia\u0142ek D, Kotulska K, Duda A, et al. Effect of mTOR inhibitors in epilepsy treatment in children with Tuberous Sclerosis Complex under 2 years of age. Neurol Ther. 2023. https:\/\/doi.org\/10.1007\/s40120-023-00476-7.","journal-title":"Neurol Ther"},{"key":"754_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41372-024-01868-9","author":"R Cavazos","year":"2024","unstructured":"Cavazos R, Patil MS, Gowda SH, et al. Sirolimus for vascular anomalies in the first year of life: a systematic review. J Perinatol. 2024. https:\/\/doi.org\/10.1038\/s41372-024-01868-9.","journal-title":"J Perinatol"},{"key":"754_CR17","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.17","author":"C Emoto","year":"2015","unstructured":"Emoto C, Fukuda T, Johnson TN, et al. Development of a pediatric physiologically based pharmacokinetic model for sirolimus: applying principles of growth and maturation in neonates and infants. CPT Pharmacometr Syst Pharmacol. 2015. https:\/\/doi.org\/10.1002\/psp4.17.","journal-title":"CPT Pharmacometr Syst Pharmacol"},{"key":"754_CR18","doi-asserted-by":"publisher","DOI":"10.1093\/ajcn\/nqz252","author":"B Koletzko","year":"2020","unstructured":"Koletzko B, Bergmann K, Brenna TJ, et al. Should formula for infants provide arachidonic acid along with DHA? A position paper of the European Academy of Paediatrics and the Child Health Foundation. Am J Clin Nutr. 2020. https:\/\/doi.org\/10.1093\/ajcn\/nqz252.","journal-title":"Am J Clin Nutr"},{"key":"754_CR19","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000000818","author":"B Delplanque","year":"2015","unstructured":"Delplanque B, Gibson R, Koletzko B, et al. Lipid quality in infant nutrition: current knowledge and future opportunities. J Pediatr Gastroenterol Nutr. 2015. https:\/\/doi.org\/10.1097\/MPG.0000000000000818.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"754_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s12887-018-1325-2","author":"R Sinclair","year":"2018","unstructured":"Sinclair R, Schindler T, Lui K, et al. Hypertriglyceridaemia in extremely preterm infants receiving parenteral lipid emulsions. BMC Pediatr. 2018. https:\/\/doi.org\/10.1186\/s12887-018-1325-2.","journal-title":"BMC Pediatr"},{"key":"754_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.earlhumdev.2023.105872","author":"K Gabriel","year":"2023","unstructured":"Gabriel K, Hovater K, Gao H, et al. Monitoring and management of hypertriglyceridemia in extremely low birth weight neonates receiving intravenous lipid emulsions: a national survey. Early Hum Dev. 2023. https:\/\/doi.org\/10.1016\/j.earlhumdev.2023.105872.","journal-title":"Early Hum Dev"},{"key":"754_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2022.931336","author":"JM Grisham","year":"2022","unstructured":"Grisham JM, Tran AH, Ellery K. Hypertriglyceridemia-induced acute pancreatitis in children: a mini-review. Front Pediatr. 2022. https:\/\/doi.org\/10.3389\/fped.2022.931336.","journal-title":"Front Pediatr"},{"key":"754_CR23","doi-asserted-by":"publisher","DOI":"10.1542\/neo.23-8-e528","author":"AP Chan","year":"2022","unstructured":"Chan AP, Robinson DT, Calkins KL. Hypertriglyceridemia in preterm infants. NeoReviews. 2022. https:\/\/doi.org\/10.1542\/neo.23-8-e528.","journal-title":"NeoReviews"},{"key":"754_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13051131","author":"R Noseda","year":"2021","unstructured":"Noseda R, Bonaldo G, Motola D, et al. Adverse event reporting with immune checkpoint inhibitors in older patients: age subgroup disproportionality analysis in VigiBase. Cancers (Basel). 2021. https:\/\/doi.org\/10.3390\/cancers13051131.","journal-title":"Cancers (Basel)"},{"key":"754_CR25","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-016-0433-x","author":"OU Osokogu","year":"2016","unstructured":"Osokogu OU, Dodd C, Pacurariu A, et al. Drug safety monitoring in children: performance of signal detection algorithms and impact of age stratification. Drug Saf. 2016. https:\/\/doi.org\/10.1007\/s40264-016-0433-x.","journal-title":"Drug Saf"},{"key":"754_CR26","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4734","author":"K Star","year":"2019","unstructured":"Star K, Sandberg L, Bergvall T, et al. Paediatric safety signals identified in VigiBase: methods and results from Uppsala Monitoring Centre. Pharmacoepidemiol Drug Saf. 2019. https:\/\/doi.org\/10.1002\/pds.4734.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"754_CR27","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s11883-025-01305-y","volume":"27","author":"JC Kelley","year":"2025","unstructured":"Kelley JC. Clinical management of dyslipidemia in infants and toddlers. Curr Atheroscler Rep. 2025;27:61. https:\/\/doi.org\/10.1007\/s11883-025-01305-y.","journal-title":"Curr Atheroscler Rep"},{"key":"754_CR28","unstructured":"Hauk L. NHLBI expert panel releases guidelines for cardiovascular health and risk reduction in children. Am Fam Physician. 2012;86(8):776\u201381."},{"key":"754_CR29","volume-title":"National Cancer Institute Common Terminology Criteria for Adverse Events ( CTCAE ) version 5.0","author":"Health NI of","year":"2017","unstructured":"Health NI of. National Cancer Institute Common Terminology Criteria for Adverse Events ( CTCAE ) version 5.0. NIH Publication; 2017."},{"key":"754_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2011.06.034","author":"TR Peterson","year":"2011","unstructured":"Peterson TR, Sengupta SS, Harris TE, et al. MTOR complex 1 regulates lipin 1 localization to control the SREBP pathway. Cell. 2011. https:\/\/doi.org\/10.1016\/j.cell.2011.06.034.","journal-title":"Cell"},{"key":"754_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/S0041-1345(03)00233-1","author":"JD Morrisett","year":"2003","unstructured":"Morrisett JD, Abdel-Fattah G, Kahan BD. Sirolimus changes lipid concentrations and lipoprotein metabolism in kidney transplant recipients. Transplant Proc. 2003. https:\/\/doi.org\/10.1016\/S0041-1345(03)00233-1.","journal-title":"Transplant Proc"},{"key":"754_CR32","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-200110150-00011","author":"RC Hoogeveen","year":"2001","unstructured":"Hoogeveen RC, Ballantyne CM, Pownall HJ, et al. Effect of sirolimus on the metabolism of apoB100-containing lipoproteins in renal transplant patients. Transplantation. 2001. https:\/\/doi.org\/10.1097\/00007890-200110150-00011.","journal-title":"Transplantation"},{"key":"754_CR33","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M113.495366","author":"M Larsson","year":"2013","unstructured":"Larsson M, Vorrsjo E, Talmud P, et al. Apolipoproteins C-I and C-III inhibit lipoprotein lipase activity by displacement of the enzyme from lipid droplets. J Biol Chem. 2013. https:\/\/doi.org\/10.1074\/jbc.M113.495366.","journal-title":"J Biol Chem"},{"key":"754_CR34","doi-asserted-by":"publisher","DOI":"10.1007\/s12265-016-9719-8","author":"V Simha","year":"2017","unstructured":"Simha V, Qin S, Shah P, et al. Sirolimus therapy is associated with elevation in circulating PCSK9 levels in cardiac transplant patients. J Cardiovasc Transl Res. 2017. https:\/\/doi.org\/10.1007\/s12265-016-9719-8.","journal-title":"J Cardiovasc Transl Res"},{"key":"754_CR35","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000001341","author":"IC Teller","year":"2017","unstructured":"Teller IC, Schoen S, Van De Heijning B, et al. Differences in postprandial lipid response to breast- or formula-feeding in 8-week-old infants. J Pediatr Gastroenterol Nutr. 2017. https:\/\/doi.org\/10.1097\/MPG.0000000000001341.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"754_CR36","doi-asserted-by":"publisher","DOI":"10.1515\/jpem-2016-0271","author":"T Kubo","year":"2017","unstructured":"Kubo T, Takahashi K, Furujo M, et al. Usefulness of non-fasting lipid parameters in children. J Pediatr Endocrinol Metab. 2017. https:\/\/doi.org\/10.1515\/jpem-2016-0271.","journal-title":"J Pediatr Endocrinol Metab"},{"key":"754_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2025.03.023","author":"J Zhou","year":"2025","unstructured":"Zhou J, Lan Y, Qiu T, et al. Efficacy and safety of high-vs low-dose sirolimus in patients with kaposiform hemangioendothelioma: a randomized clinical trial. J Am Acad Dermatol. 2025. https:\/\/doi.org\/10.1016\/j.jaad.2025.03.023.","journal-title":"J Am Acad Dermatol"}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-026-00754-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40272-026-00754-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-026-00754-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T12:10:49Z","timestamp":1784290249000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40272-026-00754-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,30]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["754"],"URL":"https:\/\/doi.org\/10.1007\/s40272-026-00754-5","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"value":"1174-5878","type":"print"},{"value":"1179-2019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,30]]},"assertion":[{"value":"15 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Akinobu Taniguchi, Basile Chr\u00e9tien, Takashi Maeda, Kazuto Ueda, Ryosuke Miura, Ryuichi Tanaka, Toshihiko Suzuki, Yukako Muramatsu, Yoshiaki Sato, and Kazuki Nishida declare that they have no potential conflicts of interest that might be relevant to the contents of this manuscript. The opinions and conclusions in this study are not necessarily those of the Uppsala Monitoring Centre or the World Health Organization.","order":1,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Conceptualization: Akinobu Taniguchi, Basile Chr\u00e9tien, and Kazuki Nishida. Methodology: Akinobu Taniguchi, Basile Chr\u00e9tien, and Kazuki Nishida. Data curation: Akinobu Taniguchi, Takashi Maeda, Kazuto Ueda, Ryosuke Miura, Ryuichi Tanaka, Toshihiko Suzuki, Yukako Muramatsu, and Yoshiaki Sato. Formal analysis: Akinobu Taniguchi (retrospective cohort analysis) and Basile Chr\u00e9tien (VigiBase analysis). Investigation: Akinobu Taniguchi, Takashi Maeda, Kazuto Ueda, Ryosuke Miura, Ryuichi Tanaka, Toshihiko Suzuki, Yukako Muramatsu, and Yoshiaki Sato. Resources: Kazuki Nishida. Supervision: Kazuki Nishida. Writing\u2014original draft: Akinobu Taniguchi and Basile Chr\u00e9tien. Writing\u2014review and editing: all authors. All authors read and approved the final manuscript.","order":2,"name":"Ethics","label":"Authors' contributions","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The datasets generated during and\/or analyzed during the current study are available from the corresponding author on reasonable request.","order":3,"name":"Ethics","label":"Data availability statement","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of Nagoya University Hospital (approval No. 2025-0285, September 26, 2025).","order":4,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The specific R code used for the analyses is available from the corresponding author on reasonable request.","order":5,"name":"Ethics","label":"Code availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":7,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}]}}